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Abstract The nitration of tyrosine residues in protein occurs
through the action of reactive oxygen and nitrogen species and is
considered a marker of oxidative stress under pathological
conditions. The most active nitrating species so far identified is
peroxynitrite, the product of the reaction between nitric oxide
and superoxide anion. Previously, we have reported that in
erythrocytes peroxynitrite irreversibly upregulates lyn, a tyrosine
kinase of the src family. In this study we investigated the possible
role of tyrosine nitration in the mechanism of lyn activation. We
found that tyrosine containing peptides modelled either on the
C-terminal tail of src kinases or corresponding to the first 15
amino acids of human erythrocyte band 3 were able to activate
lyn when the tyrosine was substituted with 3-nitrotyrosine. The
activity of nitrated peptides was shared with phosphorylated but
not with unphosphorylated, chlorinated or scrambled peptides.
Recombinant lyn src homology 2 (SH2) domain blocked the
capacity of the band 3-derived nitrotyrosine peptide to activate
lyn and we demonstrated that this peptide specifically binds the
SH2 domain of lyn. We propose that nitropeptides may activate
src kinases through the displacement of the phosphotyrosine in
the tail from its binding site in the SH2 domain. These
observations suggest a new mechanism of peroxynitrite-mediated
signalling that may be correlated with the upregulation of
tyrosine phosphorylation observed in several pathological
conditions. ß 2001 Published by Elsevier Science B.V. on be-
half of the Federation of European Biochemical Societies.
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1. Introduction
The tyrosine kinases of the src family share a high degree of
structural similarity. The src sequence consists of a poorly
conserved N-terminal segment, two conserved domains
termed src homology (SH)3 and SH2, followed by the cata-
lytic domain SH1. The SH3 and SH2 domains play a dual
role in src regulation, both being required to keep src kinases
in an inactive state and to target the enzyme to speci¢c sub-
strates by directing protein^protein interactions. The catalytic
activity of src kinases is modulated by phosphorylation of two
tyrosine residues in two opposite ways. The autophosphory-
lation of Tyr 416 (c-src numbering), located inside the cata-
lytic domain, correlates with enzyme activation, while the
phosphorylation of C-terminal tyrosine (Tyr 527) gives rise
to an inactive form of the enzyme. When the Tyr 527, located
in the tail of src kinases, is phosphorylated it interacts intra-
molecularly with the SH2 domain and triggers an enzyme
structure that forces the kinase to adopt a locked and down-
regulated conformation (for a review of src kinases see [1]) [2].
Disruption of this interaction may be one of the mechanisms
for activation of src tyrosine kinases.
In human tissues, the nitration of tyrosine residues (addi-
tion of a ^NO2 group at position 3 of the aromatic ring) has
been demonstrated under physiological conditions and has
been shown to increase signi¢cantly in in£ammatory condi-
tions and degenerative diseases. Although multiple biochemi-
cal pathways responsible for tyrosine nitration have been pro-
posed [3] so far, the most active nitrating species is
peroxynitrite. Peroxynitrite is a potent oxidizing and nitrating
species formed in a di¡usion-limited radical^radical reaction
between nitric monoxide (NO) and superoxide anion (O32 )
[4]. Peroxynitrite promotes the nitration of aromatic residues
and tyrosines thus constitute key targets for peroxynitrite. In
general, the oxidation of cysteines and tyrosines by NO-re-
lated oxidants signi¢cantly modi¢es the enzymatic function of
several target proteins [5^9], and it has also been shown that
nitration of a tyrosine residue may downregulate phosphotyr-
osine-dependent signalling in cell-free systems and cell cultures
[10,11]. Other groups as well as ourselves have reported that
peroxynitrite upregulates the activity of some kinases [12^16],
in particular tyrosine kinases of the src family in human pan-
creatic tumor tissues [9], erythrocytes [17] and synaptosomes
[18].
We recently demonstrated that two src kinases found in
erythrocytes, lyn and hck, are activated through di¡erent
pathways involving cysteine-dependent or -independent pro-
cesses [19]. We found that direct and irreversible activation of
lyn by peroxynitrite occurred through a mechanism that can-
not be explained by either cysteine or methionine oxidation.
Since the activity of src kinases is regulated by the C-terminal
tyrosine (Tyr 508 in the case of lyn), it is possible that per-
oxynitrite-induced modi¢cations may interfere with kinase
conformation, leading to its activation. MacMillan-Crow et
al. [9] found an increase in tyrosine nitration and phosphor-
ylation of c-src in human pancreatic ductal adenocarcinoma
and in adenocarcinoma cell line treated with peroxynitrite.
They suggest that the nitration of critical tyrosine residues
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could essentially mimic tyrosine phosphorylation, resulting in
kinase activation. This hypothesis is interesting and prompts
investigation of the mechanism of src kinase activation by
peroxynitrite, as well as the identi¢cation of nitrated tyrosine
residue(s). Our hypothesis is that nitrotyrosine-containing
peptides may activate lyn similarly to other speci¢c phospho-
peptides, which have been shown to activate src kinases
through the displacement of phosphorylated tail from the
SH2 domain [2]. To demonstrate this hypothesis we tested
the ability of a set of SH2-speci¢c peptides, whose phospho-
tyrosine was substituted with 3-nitrotyrosine, to modulate the
activity of lyn immunoprecipitated from human erythrocytes.
Our data show that nitrated peptides are able to activate lyn
through an SH2-dependent mechanism and support the hy-
pothesis that the nitration of speci¢c tyrosine residues may
confer a previously unrecognized gain-of-function.
2. Materials and methods
2.1. Materials
[Q32P]ATP (s 3000 Ci/mmol) was obtained from DuPont NEN
(Boston, MA, USA). Polyclonal anti-lyn and agarose-conjugated
anti-lyn antibodies were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA); Trysacryl-immobilized Protein A from
Pierce (Rockford, IL, USA); peroxidase-conjugated goat anti-rabbit
antibodies from Bio-Rad (Hercules, CA, USA). Nitrocellulose was
obtained from Shleicher and Schuell (Keene, NH, USA). All peptides
were synthesized by Neosystem (Strasbourg, France). Recombinant
glutathione S-transferase (GST)-fusion proteins: lyn 131^243 (SH2),
lyn 27^131 (SH3) and lyn 1^243 (SH2/SH3) were purchased from
Pharmingen (San Diego, CA, USA). Glutathione^Sepharose 4B was
obtained from Amersham Pharmacia Biotech (Uppsala, Sweden). All
other reagents were purchased from Sigma (St. Louis, MO, USA).
2.2. Peptide nomenclature and sequences
High a⁄nity phosphotyrosine peptide, pY; unphosphorylated pep-
tide, Y; nitrotyrosine peptide, NO2Y; chlorotyrosine peptide, ClY;
band 3-derived phosphotyrosine peptide, b3-pY; band 3-derived un-
phosphorylated peptide, b3-Y; band 3-derived nitrotyrosine peptide,
b3-NO2Y. The sequence of Y, pY, NO2Y and ClY peptides is: NH2-
Thr-Glu-Pro-Gln-Tyr-Glu-Glu-Ile-Pro-Ile-COOH in which the Tyr is
unphosphorylated, phosphorylated, or substituted with 3-nitro- or
3-chloro-tyrosine, respectively. The sequences of scrambled peptides
in which the Tyr is phosphorylated or substituted with 3-nitro-tyro-
sine, are: NH2-Glu(Ac)-Gln-Glu-Pro-Tyr-Ile-Pro-Ile-Glu-COOH, Sc1
and NH2-Tyr-Pro-Glu-Pro-Glu-Ile-Gln-Ile-Glu-COOH, Sc2. The se-
quence of the b3-Y, b3-pY and b3-NO2Y peptides is: NH2-Met-Glu-
Glu-Leu-Gln-Asp-Asp-Tyr-Glu-Asp-Met-Met-Glu-Glu-Asn-COOH
in which the Tyr is unphosphorylated, phosphorylated or substituted
with 3-nitro-tyrosine, respectively.
2.3. Cell lysis and immunoprecipitation
Washed and packed erythrocytes (150 Wl) were diluted with 300 Wl
of isotonic phosphate bu¡er, pH 7.4 and then lysed by the addition of
150 Wl of 4URIPA bu¡er (100 mM Tris, pH 7.5, 0.6 M NaCl, 4%
Triton X-100, 4% Na-deoxycholate, 0.4% SDS, 20 Wg/ml leupeptin,
20 Wg/ml aprotinin, 4 mM phenylmethanesulfonyl £uoride, 400 WM
sodium orthovanadate, 40 WM phenylarsine oxide). After 10 min of
incubation in ice, the lysate was centrifuged at 12 000Ug for 10 min at
4‡C. The supernatant was incubated for 1 h at 4‡C in a rotating wheel
with 30 Wl of Trysacryl-immobilized Protein A, clari¢ed by centrifu-
gation and incubated for 3 h at 4‡C in a rotating wheel with 20 Wl
Protein A^Trysacryl pre-adsorbed with the polyclonal anti-lyn anti-
body. The immunoprecipitate was collected by centrifugation in a
microfuge, washed twice with 1U RIPA bu¡er and twice with
50 mM Tris, 150 mM NaCl, pH 7.5 (TBS). The immunoprecipitate
was then suspended in 10 Wl TBS containing the various peptides at
the concentrations indicated, incubated at 4‡C for 2 h. The SH2
competition assay has been performed adding peptides and GST-lyn
SH2 at the same time. The samples were then subjected to a kinase
assay as described below.
2.4. In vitro kinase assay
The immunoprecipitates were washed in the kinase bu¡er (20 mM
Tris^HCl, pH 7.4, 10 mM MnCl2, 0.1 mM sodium orthovanadate)
and the kinase assay was performed using [Q32P]ATP (s 3000 Ci/
mmol) as previously described [19]. When indicated, 1 Wg of myelin
basic protein (MBP) was added to the reaction mixture as exogenous
substrate. The samples were subjected to sodium dodecyl sulfate^poly-
acrylamide gel electrophoresis (SDS^PAGE) and the gels were then
dried and exposed to X-ray ¢lm for autoradiography. The 32P-labelled
proteins were quanti¢ed by a phosphorimager instrument (Packard,
Camberra, CO, USA).
2.5. Solid phase binding assay
This procedure was used to detect the binding of biotin-labelled
band 3-derived peptides with lyn kinase or puri¢ed GST fusion pro-
teins containing lyn SH2 or SH3 domains. lyn immunoprecipitate,
obtained from erythrocyte lysate using agarose-conjugated anti-lyn
antibodies as described above, was incubated for 2 h at 4‡C with
1 mM biotinylated peptides. After extensive washing in TBS, the
lyn immunoprecipitate was suspended in 10 Wl TBS-1%SDS, centri-
fuged and 5 Wl of supernatant spotted on dry nitrocellulose paper.
Alternatively, 5 Wg of GST-lyn SH2, GST-lyn SH3 or GST alone
were incubated for 2 h at 4‡C with 1 mM biotinylated peptides.
The complex was pulled out by adding 10 Wl of glutathione^Sepharose
beads (1 h at 4‡C). The beads were then extensively washed with TBS
and bound proteins were dissociated from beads by 1% SDS (10 Wl).
The beads were removed by centrifugation and 5 Wl of the supernatant
spotted on nitrocellulose. The membrane was then blocked with 3%
bovine serum albumin/Tween 20^TBS for 2 h. To reveal the biotin-
labelled proteins, the nitrocellulose was incubated for 1 h with avidin^
biotin^peroxidase complex (Vectastain ABC kit, Vector Laboratories,
Burlingame, CA, USA), and the spots containing the biotinylated
peptide were visualized by enhanced chemiluminescence (ECL kit,
Pierce). When indicated, the ¢lters were also subjected to immunoblot
analysis using polyclonal anti-GST antibodies or polyclonal anti-lyn
antibodies, and the immunoreactivity detected by ECL.
2.6. Competition assay between band 3-derived peptides
lyn was immunoprecipitated from erythrocyte lysate using agarose-
conjugated anti-lyn antibodies and incubated 2 h at 4‡C with 2 mM
biotin-labelled b3-pY peptide. After extensive washing in TBS, lyn
immunoprecipitate was incubated for other 2 h at 4‡C with b3-
NO2Y or b3-Y (0^2 mM) and the displacement of bound b3-pY
from lyn was revealed in the supernatant after removal of beads by
centrifugation. The 100% release was obtained by adding 1% SDS
(10 Wl) to b3-pY-bound lyn immunoprecipitate. The procedure to
detect biotin-labelled peptide was carried out as described before.
The intensity of the spots was quanti¢ed by densitometric analysis
(GS-700 Imaging Densitometer, Bio-Rad, Hercules, CA, USA).
3. Results
3.1. Activation of lyn by nitrotyrosine (NO2Y) and
phosphotyrosine (pY) peptides
Liu et al. [2] have identi¢ed a short phosphotyrosine-con-
taining peptide (pY) that binds the src SH2 domain with high
a⁄nity (Kd = 40 nM). This peptide is a model peptide ob-
tained from a library in which the C-terminal phosphotyrosine
residues of c-src are partially randomized. As mentioned
above, the SH2 domain is involved in negatively regulating
src kinase activity through its intramolecular binding to a
phosphorylated tyrosine in the tail of the kinase. The pY
peptide competes for this intramolecular binding and thereby
precludes the autoinhibition of src kinases, but the unphos-
phorylated peptide (Y) does not. We performed experiments
in which the lyn kinase, immunoprecipitated from human
erythrocytes, was incubated with peptides derived from pY.
We used pY and peptides with the same amino acid sequence
but with tyrosine modi¢ed to 3-nitrotyrosine (NO2Y) or
3-chlorotyrosine (ClY). The latter tyrosine modi¢cation was
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chosen because it is of possible biological relevance, being
found in atherosclerotic tissues and considered a highly spe-
ci¢c marker of hypochlorous acid formation by myeloperox-
idase [20]. In agreement with previously published results ob-
tained with c-src [2], the incubation of lyn with 0.1^2 mM pY
peptide increased kinase autophosphorylation activity in a
dose-dependent manner (Fig. 1A). Notably, the NO2Y pep-
tide also stimulated lyn activity dose-dependently, while ClY
and Y peptides only minimally increased kinase autophos-
phorylation. Measurement of 32P incorporation into the ki-
nase revealed that pY and NO2Y peptides at 1 mM respec-
tively induced a 4.5-fold and 3.0-fold enhancement of lyn
autophosphorylation activity. Fig. 1B shows the in vitro ki-
nase assay of lyn treated with 1 mM Y, pY, NO2Y, and ClY
peptides (lanes 2^5, respectively) in the presence of the exog-
enous substrate MBP to demonstrate that pY and NO2Y also
greatly stimulated the ability of lyn to phosphorylate a sub-
strate. Treatment of lyn with the unphosphorylated peptide
(Y) at 1 mM only slightly increased kinase activity (Fig. 1B,
compare lanes 2 and 1).
To investigate the importance of the speci¢c amino acid
sequence surrounding the tyrosine residue, peptides were syn-
thesized with phosphotyrosine or nitrotyrosine in the ¢fth
position (Sc1) or in the ¢rst position (Sc2), but with the re-
maining amino acids arbitrarily scrambled. The ability of
scrambled peptides to modify lyn autophosphorylation is
shown in Fig. 2 (lanes 5^8). The results indicate that when
nitrated or phosphorylated, none of these peptides was able to
activate the kinase. These results suggest that for NO2Y the
amino acid sequence surrounding the tyrosine residue (Glu at
+1 and +2) confers the ability to activate lyn, a ¢nding pre-
viously reported for pY also [2]. Bearing in mind these earlier
results, it could therefore be hypothesized that the NO2Y
peptide is able to activate lyn through a mechanism that in-
volves binding to the SH2 domain. The following experiments
were performed to provide further proof of this hypothesis.
3.2. Activation of lyn kinase by b3-NO2Y and b3-pY peptides
derived from band 3
Recent data [21] have shown that, in human erythrocytes,
Tyr 8 and Tyr 21 of the cytoplasmic domain of band 3 when
phosphorylated by the non-src tyrosine kinase syk, act as a
docking site for the SH2 domain of lyn, which subsequently
phosphorylates band 3 at additional secondary sites (Tyr 359
and Tyr 904). It is therefore important to establish if a nitro-
tyrosine-containing peptide, whose sequence is expressed in
proteins, could modify lyn kinase activity. Peptides corre-
sponding to the ¢rst 15 amino acids of band 3 were synthe-
sized and Tyr 8 was either phosphorylated or nitrated. With
Fig. 1. Activation of lyn tyrosine kinase by pY and NO2Y peptides.
A: lyn immunoprecipitate, obtained from human erythrocytes, was
incubated for 2 h at 4‡C with 0.1^2 mM of non-phosphorylated (Y,
F), phosphorylated (pY, R), nitrated (NO2Y, b), and chlorinated
(ClY, 8) peptides. The nomenclature and peptide sequences are re-
ported in Section 2. The samples were subjected to in vitro kinase
assay with [Q32P]ATP, and lyn activity was measured by quanti¢ca-
tion of 32P incorporation into the protein using a phosphorimager
Instrument. lyn activity was expressed as total counts (mean þ S.D.
of three separate experiments). B: Autoradiography of the in vitro
kinase assay of lyn immunoprecipitate treated with 1 mM of Y, pY,
NO2Y, and ClY (lanes 2^5, respectively) in the presence of the
exogenous substrate MBP. Lane 1, lyn immunoprecipitate incubated
without any peptide. The samples were resolved on 15% SDS^
PAGE, dried and exposed to X-ray ¢lm. A representative of three
experiments with consistent results is shown. The molecular mass
markers in kDa are indicated on the right.
Fig. 2. E¡ects of nitrated and phosphorylated scrambled peptides
Sc1 and Sc2 on lyn activity. lyn immunoprecipitate was incubated
with the indicated peptides at a concentration of 1 mM. The se-
quences of Sc1 and Sc2 are reported in Section 2. The samples were
subjected to in vitro kinase assay with [Q32P]ATP and analyzed by
10% SDS^PAGE. lyn activity was measured as in the legend to Fig.
1. lyn activity was expressed as a percentage of the value in control
sample (100%). Data are the mean þ S.D. of three separate experi-
ments. The upper panel shows a representative autoradiography of
the samples described.
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respect to the sequence of pY peptide, these peptides maintain
the residue Glu at +1 and possess a di¡erent acidic residue at
+2 (Asp). The results, shown in Fig. 3, showed that both b3-
pY and b3-NO2Y peptides strongly stimulated lyn autophos-
phorylation activity. Interestingly, band 3-derived peptides
possessed a higher capacity to activate lyn than either pY or
NO2Y (compare lanes 3 and 4 of Fig. 2 with lanes 3 and 4 of
Fig. 3). Measurement of 32P incorporation showed that the
b3-pY and b3-NO2Y peptides stimulated lyn autophosphory-
lation activity 6.5-fold and 4.5-fold, respectively.
3.3. lyn SH2 domain abolishes lyn activation induced by b3-pY
and b3-NO2Y
To test the possibility that kinase activation induced by b3-
pY and b3-NO2Y involves peptide binding to a regulatory
domain of lyn, we used recombinant GST fusion proteins
containing either lyn SH2 and/or lyn SH3 domains. These
GST fusion proteins were added to lyn immunoprecipitate
in the presence of b3-pY or b3-NO2Y peptides. Interestingly,
we found that GST fusion proteins containing lyn SH2 do-
main (lyn 1^243 and lyn 131^243, see Fig. 4A) abolished the
kinase activation induced by b3-pY and by b3-NO2Y, while
GST-lyn 27^131, which contains only the lyn SH3 domain,
did not (Fig. 4B). These results provide indirect evidence
that b3-NO2Y and b3-pY peptides may interfere with lyn
activity by competing to bind the SH2 domain to the phos-
phorylated tail. As expected, neither the incubation of lyn
with GST-lyn 131^243 without peptides (Fig. 4B, lane 6) or
the treatment of lyn immunoprecipitate with GST protein had
any e¡ect on kinase activity (result not shown).
3.4. The b3-NO2Y and b3-pY peptides speci¢cally bind the
SH2 domain of lyn
To support our hypothesis further, we used b3-pY and b3-
NO2Y peptides labelled with biotin at the N-terminal posi-
tion, to demonstrate their binding to the lyn SH2 domain in a
solid phase binding assay. We ¢rst tested the ability of these
biotinylated peptides to activate lyn in the in vitro kinase
Fig. 3. Activation of lyn autophosphorylation activity by b3-pY and
b3-NO2Y peptides. lyn immunoprecipitate was incubated with 1 mM
of the indicated peptides derived from the ¢rst 15 amino acids of
band 3. The sequences of the peptides are reported in Section 2.
The experimental procedure was as in Fig. 2.
Fig. 4. lyn SH2 domain abolishes the activation of lyn induced by b3-pY and b3-NO2Y peptides. B: lyn immunoprecipitate was incubated with
b3-pY (left) or b3-NO2Y (right) both at 1 mM in the presence of 1 mg/ml of puri¢ed GST-lyn 27^131 (lane 3), GST-lyn 1^243 (lane 4) or
GST-lyn 131^243 (lane 5). Lane 1 represents lyn immunoprecipitate incubated alone and lane 2 the lyn immunoprecipitate incubated with b3-
pY and b3-NO2Y peptides. Lane 6, lyn immunoprecipitate incubated with 1 mg/ml of GST-lyn 131^243 without peptides. The samples were
subjected to in vitro kinase assay with [Q32P]ATP, and analyzed by 10% SDS^PAGE. The gels were dried and exposed to X-ray ¢lms for auto-
radiography. A representative of three experiments with consistent results is shown. The lyn protein regions used as GST fusion proteins are re-
ported in A.
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assay and found that both biotinylated and non-biotinylated
peptides activated lyn in a similar manner (data not shown).
As shown in Fig. 5, when the immunoprecipitate of lyn was
treated with biotinylated peptides (1 mM), as described in
Section 2, the biotin detection revealed a very intense reaction in the spots corresponding to samples treated with b3-pY and
b3-NO2Y peptides. When polyclonal anti-lyn antibodies were
applied on the same nitrocellulose we found that all the sam-
ples contained comparable amounts of protein (Fig. 5). In
addition, to ensure that the agarose-conjugated anti-lyn anti-
bodies used to immunoprecipitate lyn from erythrocytes did
not bind the biotinylated peptides, we performed control ex-
periments in which agarose-conjugated anti-lyn antibodies
(without lyn kinase) were treated with biotinylated peptides
(1 mM) and the samples processed as described before. We
detected no reaction in these samples (results not shown).
We also performed a solid phase binding assay to demon-
strate whether the band 3-derived nitropeptide may compete
with the phosphopeptide bound to lyn. We found that b3-
NO2Y, but not b3-Y, induced the displacement of b3-pY
from lyn in a dose-dependent manner (Fig. 6, lanes 2^5).
The displacement, however, occurred at relatively high con-
centration of nitropeptide suggesting a lower e⁄ciency with
respect to the phosphopeptide.
These results clearly demonstrate a binding of b3-pY and
b3-NO2Y to the lyn kinase, but we did not know exactly
which domain of lyn was involved. To resolve this question,
we incubated both the GST fusion proteins (lyn 131^243 or
lyn 27^131) and GST alone with biotinylated peptides
(1 mM). After the addition of glutathione^Sepharose beads
to separate the GST-containing complexes, we identi¢ed the
domain implicated in the binding using ABC staining. As
shown in Fig. 7, biotin detection unambiguously demonstrates
that the lyn SH2 domain (lyn 131^243) binds both b3-pY and
b3-NO2Y peptides with the same e⁄ciency and that the bind-
Fig. 5. Binding of b3-pY and b3-NO2Y peptides to lyn tyrosine ki-
nase. Solid phase binding assay of lyn, immunoprecipitated by aga-
rose-conjugated anti-lyn polyclonal antibodies, with b3-pY and b3-
NO2Y peptides labelled with biotin. lyn immunoprecipitate was in-
cubated for 2 h at 4‡C with the biotinylated peptides (1 mM). Each
samples (5 Wl) was spotted on the nitrocellulose and binding was re-
vealed by the ABC detection procedure (Vectastain ABC kit, Vec-
tor). The reaction was visualized on nitrocellulose by ECL kit
(Pierce) (left panel). The same nitrocellulose was then probed with
anti-lyn polyclonal antibodies and the immunoreactivity detected by
ECL to verify that comparable amounts of lyn were present in each
spot (right panel). A representative of three experiments with consis-
tent results is shown.
Fig. 6. Competition assay between b3-pY and b3-NO2Y peptides.
Biotinylated b3-pY (2 mM) was ¢rstly bound to lyn immunoprecipi-
tate and then the peptide was released from the kinase by b3-
NO2Y, b3-Y (lanes 2^5, black and white columns, respectively) or
1% SDS (lane 1 and hatched column). The presence of biotinylated
b3-pY in the supernatant was visualized on nitrocellulose by ABC
detection procedure and ECL (upper panel). The spots were quanti-
¢ed by densitometric analysis (bottom panel).
Fig. 7. Binding of b3-pY and b3-NO2Y peptides to lyn SH2 do-
main. Solid phase binding assay of puri¢ed recombinant GST-lyn
131^243 (SH2), GST-lyn 27^131 (SH3), and GST alone with biotin-
labelled b3-pY and b3-NO2Y peptides (1 mM). The reaction was
carried out for 2 h at 4‡C and the GST complexes were then linked
by glutathione^Sepharose beads (10 Wl). 5 Wl of each sample was
spotted on the nitrocellulose and the binding between GST fusion
proteins and biotinylated peptides was revealed as described in Fig.
5 (upper panel). To verify that comparable amounts of GST were
present in each spot, the same nitrocellulose was probed with anti-
GST polyclonal antibodies and the immunoreactivity detected by
ECL (bottom panel). A representative of three experiments with
consistent results is shown.
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ing was speci¢c, since neither lyn SH3 (lyn 27^131) or GST
alone showed any reaction. By applying anti-GST polyclonal
antibodies on the nitrocellulose used in biotin detection we
showed that all the samples contained comparable amounts
of proteins (Fig. 7, bottom).
4. Discussion
This study provides the ¢rst evidence of a role of nitroty-
rosine as a potential activator of tyrosine kinases of the src
family. We show that lyn, a src tyrosine kinase isolated from
human erythrocytes, may be upregulated by nitrotyrosine-
containing peptides. The activation of lyn was characteristic
of phosphotyrosine- and nitrotyrosine-containing peptides,
since a peptide with the same amino acid sequence but con-
taining unmodi¢ed tyrosine or chlorotyrosine did not a¡ect
lyn activity (Fig. 1).
The amino acid sequence of the nitrated peptide was iden-
tical to that of the high a⁄nity SH2-binding phosphotyrosine
peptide (pY), described by Liu et al. [2], and, as previously
demonstrated for pY, the amino acids surrounding the nitro-
tyrosine are critical. In fact, two scrambled peptides, in which
the acidic amino acids at +1 and +2 were substituted, lost the
ability to activate lyn (Fig. 2).
The SH2 domain of src kinases is involved in negatively
regulating kinase activity, which it does by binding with the
phosphorylated tyrosine in the tail of the kinase; pY competes
for this intramolecular binding. Our results suggest that sub-
stitution of phosphotyrosine with nitrotyrosine can cause lyn
activation through the same mechanism and, thus, that nitra-
tion can mimic phosphorylation. Tyrosine nitration mimics
phosphorylation with respect to the charge of the aromatic
residue, since the addition of 3NO2 to position 3 of the ar-
omatic ring lowers the pKa of the tyrosine hydroxyl group to
7.2 [22] and, thus, at slight alkaline pHs adds a negative
charge.
We recently reported that peroxynitrite treatment of eryth-
rocytes induced the activation of lyn through an irreversible
mechanism [19]. As one of the major modi¢cations induced by
peroxynitrite is the nitration of tyrosine residues, the present
results suggest that lyn upregulation may occur through the
nitration of a tyrosine residue(s) in a substrate with high af-
¢nity for the SH2 domain. Although several nitrated sub-
strates can in principle perform this function, we suggest
that in erythrocytes a likely candidate may be band 3, the
major tyrosine phosphorylation site of these cells. This hy-
pothesis is based on two observations. First, we have shown
that peroxynitrite treatment of human erythrocytes resulted in
tyrosine nitration of the 22 kDa cytoplasmic N-terminal do-
main of the anion channel band 3 [23] and, second, we show
in this study that the nitropeptide b3-NO2Y, corresponding to
the ¢rst 15 amino acids of band 3 which include one of the
major phosphorylation sites of band 3 (Tyr 8), is able to
activate lyn strongly in a manner comparable to that of b3-
pY (Fig. 3). Moreover, the exogenous addition of the SH2
domain of lyn abolished b3-pY- and b3-NO2Y-dependent ac-
tivation of lyn (Fig. 4), and we also demonstrated that the
SH2 domain is speci¢cally involved in the binding of either
b3-pY or b3-NO2Y (Fig. 7). These results thus suggest that
not only phosphorylation but also nitration of the cytoplas-
mic N-terminal domain of band 3 can cause lyn activation
through a SH2-dependent mechanism and, since nitration is
irreversible, at least in erythrocytes (our unpublished results),
lyn upregulation was not downregulated by glucose metabolic
recovery [19]. Furthermore, the ¢nding that a nitrated sub-
strate with SH2 binding a⁄nity acquires the ability to activate
a src kinase suggest that other substrates apart from band 3
may have the same property as demonstrated by our results
with the NO2Y peptide.
The hypothesis that nitration may be the mechanism
through which src kinases are activated has recently been
suggested [9]. These authors showed that when c-src is ex-
tracted from human pancreatic adenocarcinomas, it is both
activated and nitrated, leading to the hypothesis that the ni-
tration of critical tyrosine residues within c-src might alter
kinase regulation, thereby increasing its activity. Although
nitration of the regulatory tyrosine in the tail would be ex-
pected to downregulate the kinase (as suggested by the inter-
changeability of pY and NO2Y peptides), it remains possible
that the same c-src kinase possesses a tyrosine residue(s) that,
when nitrated, may induce kinase activation through still un-
characterized intramolecular or intermolecular mechanisms.
Several recent reports have shown that peroxynitrite can
also alter other signal transduction processes, resulting in
the activation of mitogen-activated protein kinases [15] or in
the inhibition of phosphotyrosine- and phosphoinositide-de-
pendent signalling [12,24]. However, the upregulation of src
kinases mediated by nitrating agents may induce rapid and
uncontrolled cell growth and transformation, particularly in
tissues overexpressing the inducible nitric oxide synthase. We
therefore suggest that tyrosine nitration may represent a gain-
of-function in the regulation of src kinases and may play a
signi¢cant role in several pathological conditions.
Acknowledgements: We thank Dr. Tamara C. Petrucci for helpful
comments and discussions. This work was supported in part by Isti-
tuto Superiore di Sanita', Roma, Italy, Research Project 98/JR: ‘Nat-
ural antioxidant and e¡ects on chronic-degenerative diseases’.
References
[1] Thomas, S.M. and Brugge, J.S. (1997) Annu. Rev. Cell Dev.
Biol. 13, 513^609.
[2] Liu, X., Bordeur, S.R., Gish, G., Songyang, Z., Cantley, L.C.,
Laudano, A.P. and Pawson, T. (1993) Oncogene 8, 1119^1126.
[3] Ischiropoulos, H. (1998) Arch. Biochem. Biophys. 356, 1^11.
[4] Beckman, J.S., Beckman, T.W., Chen, J. and Marshall, P.A.
(1990) Proc. Natl. Acad. Sci. USA 87, 1620^1624.
[5] Lander, H.M., Hajjar, D.P., Hempstead, B.L., Mirza, U.A.,
Chait, B.T., Campbell, S. and Quilliam, L.A. (1997) J. Biol.
Chem. 272, 4323^4326.
[6] MacMillan-Crow, L.A., Crow, J.P. and Thompson, J.A. (1998)
Biochemistry 37, 1613^1622.
[7] Kuhn, D.M., Aretha, C.W. and Geddes, T.J. (1999) J. Neurosci.
19, 10289^10294.
[8] Takakura, K., Beckman, J.S., MacMillan-Crow, L.A. and Crow,
J.P. (1999) Arch. Biochem. Biophys. 369, 197^207.
[9] MacMillan-Crow, L.A., Greendorfer, J.S., Vickers, S.M. and
Thompson, J.A. (2000) Arch. Biochem. Biophys. 377, 350^356.
[10] Kong, S.-K., Yim, M., Stadman, E.R. and Chock, P.B. (1996)
Proc. Natl. Acad. Sci. USA 93, 3377^3382.
[11] Gow, A.J., Duran, D., Malcom, S. and Ischiropoulos, H. (1996)
FEBS Lett. 385, 63^66.
[12] Li, X., De Sarno, P., Song, L., Beckman, J.S. and Jope, R. (1998)
Biochem. J. 331, 599^606.
[13] van der Vliet, A., Hristova, M., Cross, C.E., Eiserich, J.P. and
Goldkorn, T. (1998) J. Biol. Chem. 273, 31860^31866.
[14] Go, Y.M., Patel, R.P., Maland, M.C., Park, H., Beckman, J.S.,
Darley-Usmar, V.M. and Jo, H. (1999) Am. J. Physiol. 277,
H1647^H1653.
FEBS 25134 13-8-01
C. Mallozzi et al./FEBS Letters 503 (2001) 189^195194
[15] Schieke, S.M., Briviba, K., Lars-Oliver, K. and Sies, H. (1999)
FEBS Lett. 448, 301^303.
[16] Jope, R.S., Zhang, L. and Song, L. (2000) Arch. Biochem. Bio-
phys. 376, 365^370.
[17] Mallozzi, C., Di Stasi, A.M.M. and Minetti, M. (1999) FEBS
Lett. 456, 201^206.
[18] Di Stasi, A.M.M., Mallozzi, C., Macchia, G., Petrucci, T.C. and
Minetti, M. (1999) J. Neurochem. 73, 727^735.
[19] Mallozzi, C., Di Stasi, A.M. and Minetti, M. (2001) Free Radic.
Biol. Med. 30, 1108^1117.
[20] Heinecke, J.W. (1999) FASEB J. 13, 1113^1120.
[21] Brunati, A.M., Bordin, L., Clari, G., James, P., Quadroni, M.,
Baritono, E., Pinna, L.A. and Donella-Deana, A. (2000) Blood
96, 1550^1557.
[22] Sokolovsky, M., Riordan, J.F. and Vallee, B.L. (1967) Biochem.
Biophys. Res. Commun. 27, 20^25.
[23] Mallozzi, C., Di Stasi, A.M.M. and Minetti, M. (1997) FASEB J.
11, 1281^1290.
[24] Saeki, M. and Maeda, S. (1999) Neurosci. Res. 33, 325^328.
FEBS 25134 13-8-01
C. Mallozzi et al./FEBS Letters 503 (2001) 189^195 195
